Triple combination of vemurafenib, cobimetinib, and atezolizumab in real clinical practice in the Russian Federation: results of the A1 cohort of the ISABELLA study
Triple combination of atezolizumab, vemurafenib, and cobimetinib had proven its efficacy and tolerability in real settings. No impact of potential predictive biomarkers was seen (NCT05402059).
Authors
- Igor Utyashev (ORCID: https://orcid.org/0000-0003-0002-4814)
- Ivan I. Butkov
- Lev Demidov (ORCID: https://orcid.org/0000-0002-8562-6082)
- Natalia Beliaeva (ORCID: https://orcid.org/0000-0001-7788-165X)
- К. V. Menshikov (ORCID: https://orcid.org/0000-0003-3734-2779)
- Н. А. Савелов
- Yu.M. Kolontareva
- K. G. Babina
- Yu. V. Vakhabova
- Kristina V. Orlova (ORCID: https://orcid.org/0000-0002-0442-5917)
- Е. В. Карабина (ORCID: https://orcid.org/0000-0001-6062-5318)
- V. D. Sychev (ORCID: https://orcid.org/0000-0002-9498-3719)
- Игорь Вячеславович Самойленко (ORCID: https://orcid.org/0000-0001-7150-5071)
- Maksim V. Zinkevich (ORCID: https://orcid.org/0009-0005-9106-955X)
- Natalia V. Zhukova (ORCID: https://orcid.org/0000-0002-0619-2205)
- M. Е. Ivannikov (ORCID: https://orcid.org/0009-0007-0407-0953)
- Vera V. Chernova
- Alexander Yurchenkov
- Mikhail Volkonsky
- E. V. Kogay
- Tatyana L. Moskovkina
- Kseniya A. Moshkova
- Olga V. Plishkina
- Oxana S. Cheplukhova
Institutions
- Nizhny Novgorod Regional Clinical Oncology Center (RU)
- City Clinical Oncology Center (RU)
- Orenburg Regional Clinical Oncology Center (RU)
- Kirov State Medical Academy (RU)
- Guz "Tul'skiy Oblastnoy Onkologicheskiy Dispanser (RU)
- Murmansk Regional Oncology Center (RU)
- State Healthcare Institution "Regional Clinical Oncological Dispensary" (RU)
- Volgograd Regional Clinical Oncology Center (RU)
- Tyumen State Medical University (RU)
- Moscow City Oncology Hospital №62 (RU)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-10-14
- DOI
- https://doi.org/10.3389/fonc.2024.1395378
- Citations
- 5
- Primary Topic
- Melanoma and MAPK Pathways
- Type
- article
- Field-Weighted Citation Impact
- 1.17